Get the latest news, insights, and market updates on NUVB (Nuvation Bio Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
NEW YORK, February 09, 2026--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to the ongoing global SIGMA study (also known as G203; NCT05303519) of safusidenib that expands it to a Phase 3 trial. SIGMA is evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-risk or high-grade IDH1-mutant astrocytoma Feb 9, 2026 - $NUVB
Merchants Bancorp And 2 Other Growth Stocks Insiders Are Banking On
As the U.S. stock market kicks off February with a robust start, highlighted by the Dow Jones Industrial Average's 515-point surge and the S&P 500 nearing record highs, investors are keenly observing growth companies with significant insider ownership. In this dynamic environment, stocks like Merchants Bancorp that demonstrate strong insider confidence can be particularly appealing to investors looking for potential growth opportunities amidst favorable market conditions. Feb 3, 2026 - $NUVB
Assessing Nuvation Bio (NUVB) Valuation After Bullish Analyst Calls On Ibtrozi And mIDH1 Glioma Potential
Why recent analyst commentary is putting Nuvation Bio back on investors’ radar Recent research updates on Nuvation Bio (NUVB) have drawn investor attention, as multiple firms highlighted stronger than expected early demand for the Ibtrozi franchise and future potential tied to the company’s mIDH1 glioma program. See our latest analysis for Nuvation Bio. Even with recent enthusiasm around Ibtrozi and the mIDH1 glioma program, Nuvation Bio’s share price has been volatile. The 30 day share price... Feb 1, 2026 - $NUVB
Turist Financial Remains a Buy on Nuvation Bio (NUVB)
Nuvation Bio Inc. (NYSE:NUVB) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 27, Gregory Renza from Turist Financial reiterated a Buy rating on the stock and raised the price target from $11 to $13. Earlier on January 23, Soumit Roy from JonesTrading assigned a Buy rating on Nuvation […] Jan 30, 2026 - $NUVB
Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors
Nuvation Bio Inc. (NYSE:NUVB) is one of the best high short interest stocks with biggest upside potential. On January 27, Truist raised its price target on Nuvation Bio to $13 from $11 and maintained a Buy rating, citing the Ibtrozi franchise’s robust initial performance as part of a Q4 2025 earnings preview for the biotech […] Jan 30, 2026 - $NUVB
Nuvation Bio price target raised to $13 from $11 at Truist
Truist raised the firm’s price target on Nuvation Bio (NUVB) to $13 from $11 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in Biotech. The firm believes the Ibtrozi franchise has shown robust opportunity out of the gate, with stronger-than-anticipated uptake, despite seasonal headwinds, positioning Ibtrozi as the ROS1 agent of choice versus competitors, the analyst tells investors in a research note. Claim 50% Off TipRanks PremiumUnlock hedge fund Jan 28, 2026 - $NUVB
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations
We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Nuvation Bio Inc. stands seventh on our list among the best oncology stocks. TheFly reported on January 12 that H.C. Wainwright reduced its price target on NUVB to $17 from $18 while maintaining a Buy rating. The firm said the company’s […] Jan 20, 2026 - $NUVB
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NYSE:NUVB) is one of the Stocks to Buy Under $10 with High Potential. On January 15, Soumit Roy from JonesTrading reiterated a Buy rating on the stock and raised the price target from $10 to $12. Earlier, on January 13, Gregory Renza from Truist Financial also reiterated a Buy rating on Nuvation […] Jan 19, 2026 - $NUVB
Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth
If you are wondering whether Nuvation Bio at around US$5.85 is priced for its future potential or already reflects high expectations, the next sections will walk through what the numbers are saying about value. The stock has seen sharp swings, with a 27.2% decline over the last 7 days and a 31.3% fall over the last 30 days, even though the 1 year return sits at 133.1% and the 3 year return at 147.9%. These moves are set against the backdrop of ongoing interest in early stage oncology names... Jan 17, 2026 - $NUVB
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple